Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 704980, 5 pages
http://dx.doi.org/10.1155/2014/704980
Clinical Study

Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines

Department of Infectious Diseases, Rural Development Trust Hospital, Kadiri Road, Bathalapalli, Anantapur, Andhra Pradesh 515661, India

Received 11 June 2014; Revised 28 November 2014; Accepted 29 November 2014; Published 16 December 2014

Academic Editor: Roja Rahimi

Copyright © 2014 Gerardo Alvarez-Uria et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Global Tuberculosis Control, World Health Organization, Geneva, Switzerland, 2012.
  2. S. D. Lawn, A. D. Harries, G. Meintjes, H. Getahun, D. V. Havlir, and R. Wood, “Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa,” AIDS, vol. 26, no. 17, pp. 2121–2133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. WHO, Global Tuberculosis Control, WHO, Geneva, Switzerland, 2011.
  4. WHO, Treatment of Tuberculosis: Guidelines for National Programmes, WHO/CDS/TB/2003.313, 3rd edition, 2003.
  5. F. A. Khan, J. Minion, A. Al-Motairi, A. Benedetti, A. D. Harries, and D. Menzies, “An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection,” Clinical Infectious Diseases, vol. 55, no. 8, pp. 1154–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Alvarez-Uria, M. Midde, R. Pakam, and P. K. Naik, “Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients,” BioMed Research International, vol. 2014, Article ID 937817, 7 pages, 2014. View at Publisher · View at Google Scholar
  7. Office of the Registrar General & Census Commissioner, Census of India, New Delhi, India, 2011.
  8. G. Alvarez-Uria, M. Midde, R. Pakam, and P. K. Naik, “Gender differences, routes of transmission, sociodemographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India,” Infectious Disease Reports, vol. 4, no. 1, article e19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Alvarez-Uria, M. Midde, R. Pakam, S. Kannan, L. Bachu, and P. K. Naik, “Factors associated with late presentation of HIV and estimation of antiretroviral treatment need according to CD4 lymphocyte count in a resource-limited setting: data from an HIV cohort study in India,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2012, Article ID 293795, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Alvarez-Uria, R. Pakam, M. Midde, and P. K. Naik, “Entry, retention, and virological suppression in an HIV cohort study in India: description of the cascade of care and implications for reducing HIV-related mortality in low- and middle-income countries,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2013, Article ID 384805, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Alvarez-Uria, M. Midde, R. Pakam, L. Bachu, and P. K. Naik, “Effect of formula feeding and breastfeeding on child growth, infant mortality, and HIV transmission in children born to HIV-infected pregnant women who received triple antiretroviral therapy in a resource-limited setting: data from an HIV cohort study in India,” ISRN Pediatrics, vol. 2012, Article ID 763591, 9 pages, 2012. View at Publisher · View at Google Scholar
  12. G. Alvarez-Uria, M. Midde, R. Pakam, and P. K. Naik, “Initial antituberculous regimen with better drug penetration into cerebrospinal fluid reduces mortality in HIV infected patients with tuberculous meningitis: data from an HIV observational cohort study,” Tuberculosis Research and Treatment, vol. 2013, Article ID 242604, 7 pages, 2013. View at Publisher · View at Google Scholar
  13. Ministry of Health and Family Welfare India, Technical and Operational Guideline for Tuberculosis Control, 2005.
  14. F. E. Harrell Jr., R. M. Califf, D. B. Pryor, K. L. Lee, and R. A. Rosati, “Evaluating the yield of medical tests,” The Journal of the American Medical Association, vol. 247, no. 18, pp. 2543–2546, 1982. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Alvarez-Uria, P. K. Naik, R. Pakam, L. Bachu, and M. Midde, “Natural history and factors associated with early and delayed mortality in HIV-infected patients treated of tuberculosis under directly observed treatment short-course strategy: a prospective cohort study in India,” Interdisciplinary Perspectives on Infectious Diseases, vol. 2012, Article ID 502012, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Alvarez-Uria, M. Midde, R. Pakam, and P. K. Naik, “Diagnostic and prognostic value of serum albumin for tuberculosis in HIV infected patients eligible for antiretroviral therapy: datafrom an HIV cohort study in India,” BioImpacts, vol. 3, no. 3, pp. 123–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Kwan and J. D. Ernst, “HIV and tuberculosis: a deadly human syndemic,” Clinical Microbiology Reviews, vol. 24, no. 2, pp. 351–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Brindle, J. Odhiambo, and D. Mitchison, “Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis,” BMC Pulmonary Medicine, vol. 1, article 2, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Ruslami, A. R. Ganiem, S. Dian et al., “Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial,” The Lancet Infectious Diseases, vol. 13, no. 1, pp. 27–35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. World Health Organization, Treatment of Tuberculosis: Guidelines for National Programmes, 4th edition, 2009.
  21. D. Menzies, A. Benedetti, A. Paydar et al., “Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis,” PLoS Medicine, vol. 6, no. 9, Article ID e1000150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Swaminathan, G. Narendran, P. Venkatesan et al., “Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 743–751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. E. Bliven-Sizemore, J. L. Johnson, S. Goldberg, W. J. Burman, M. E. Villarino, and R. E. Chaisson, “Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment,” International Journal of Tuberculosis and Lung Disease, vol. 16, no. 4, pp. 473–479, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. R. Babu and R. Laxminarayan, “The unsurprising story of MDR-TB resistance in India,” Tuberculosis, vol. 92, no. 4, pp. 301–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Deepa, S. Achanta, J. Jaju et al., “The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of andhra pradesh, India,” PLoS ONE, vol. 8, no. 10, Article ID e76189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Narendran, P. A. Menon, P. Venkatesan et al., “Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy,” Clinical Infectious Diseases, vol. 59, pp. 1798–1804, 2014. View at Google Scholar
  27. G. Alvarez-Uria, R. Pakam, M. Midde, and P. K. Naik, “Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India,” Journal of the International AIDS Society, vol. 17, Article ID 19251, 2014. View at Google Scholar
  28. A. B. Suthar, S. D. Lawn, J. del Amo et al., “Antiretroviral therapy for prevention of tuberculosis in adults with hiv: a systematic review and meta-analysis,” PLoS Medicine, vol. 9, no. 7, Article ID e1001270, 2012. View at Publisher · View at Google Scholar · View at Scopus